DELAYED-RELEASE DIMETHYL FUMARATE-ASSOCIATED LYMPHOPENIA

被引：0
|
作者：
Chan, Andrew [1 ]
Fox, Robert J. [2 ]
Bar-Or, Amit [3 ,4 ]
Chen, Chongshu [5 ]
Fam, Sami [5 ]
Gold, Ralf [1 ]
Hanna, Jerome [5 ]
Mehta, Devangi [5 ]
Phillips, J. Theodore [6 ]
机构：
[1] Univ Bern, Bern Univ Hosp, Inselspital, Bern, Switzerland
[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Biogen, Cambridge, MA USA
[6] Baylor Inst Immunol Res, Dallas, TX USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
D O I：
10.1136/jnnp-2019-ABN-2.146
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
159
引用
收藏
页码：E53 / E53
页数：1
相关论文
共 50 条
  • [41] Efficacy of delayed-release dimethyl fumarate in young adults with RRMS: an integrated analysis of DEFINE and CONFIRM
    Soman, T.
    Ordonez, C. L.
    Castrillo-Viguera, C.
    Zhang, A.
    Potts, J.
    Marantz, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 760 - 761
  • [42] Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)
    Alroughani, Raed
    Das, Rajiv
    Penner, Natasha
    Pultz, Joe
    Taylor, Catherine
    Eraly, Satish
    PEDIATRIC NEUROLOGY, 2018, 83 : 19 - 24
  • [43] Absolute Lymphocyte Counts Are Not a Biomarker of Clinical Response in Patients Treated With Delayed-Release Dimethyl Fumarate
    Longbrake, Erin
    Mao-Draayer, Yang
    Matthews, Paul M.
    Foley, John
    Zielinski, Tomasz
    Chen, Chongshu
    Mokliatchouk, Oksana
    Parks, Becky
    Sharma, Ankur
    Xing, Diana
    Kapadia, Shivani
    Bame, Eris
    NEUROLOGY, 2020, 94 (15)
  • [44] Dimethyl fumarate: risk of PML associated with mild lymphopenia
    Reactions Weekly, 2021, 1839 (1) : 4 - 4
  • [45] Factors associated with dimethyl fumarate-induced lymphopenia
    Sainz de la Maza, Susana
    Medina, Silvia
    Villarrubia, Noelia
    Costa-Frossard, Lucienne
    Monreal, Enric
    Tejeda-Velarde, Amalia
    Rodriguez-Martin, Eulalia
    Roldan, Ernesto
    Alvarez-Cermeno, Jose C.
    Villar, Luisa M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 398 : 4 - 8
  • [46] Differential recovery from relapse between treatment groups in the CONFIRM study of delayed-release dimethyl fumarate
    Chan, A.
    Phillips, J. T.
    Fox, R. J.
    Zhang, A.
    Potts, J.
    Kurukulasuriya, N. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 297 - 297
  • [47] Differential recovery from relapse between treatment groups in the CONFIRM study of delayed-release dimethyl fumarate
    Chan, A.
    Phillips, J. T.
    Fox, R. J.
    Zhang, A.
    Okwuokenye, M.
    Kurukulasuriya, N. C.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 110 - 110
  • [48] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [49] BUDGET IMPACT OF ADDING DELAYED-RELEASE DIMETHYL FUMARATE TO THE FORMULARY FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS
    Mauskopf, J. A.
    Fay, M.
    Iyer, R.
    Livingston, T.
    VALUE IN HEALTH, 2014, 17 (03) : A58 - A58
  • [50] ESTIMATION OF TIME TO REACH RRMS EDSS HEALTH STATES ≥ 7.0 OR SPMS FOR DELAYED-RELEASE DIMETHYL FUMARATE
    Walker, A.
    Berling, M.
    Malmenaes, M.
    Brodtkorb, T.
    Alvarez-Reyes, M.
    VALUE IN HEALTH, 2015, 18 (03) : A279 - A279
12345